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ABSTRACT: Understanding the transitions between polymorphs is essential in the development of strategies for manufacturing and 
maximizing the efficiency of pharmaceuticals. However, this can be extremely challenging: crystallization can be influenced by subtle 
changes in environment such as temperature and mixing intensity or even imperfections in the crystallizer walls. Here, we highlight 
the importance of in situ measurements in understanding crystallization mechanisms, where a segmented flow crystallizer was used 
to study the crystallization of the pharmaceuticals urea:barbituric acid (UBA) and carbamazepine (CBZ).  The reactor provides highly 
reproducible reaction conditions, while in situ synchrotron powder X-ray diffraction (PXRD) enables us to monitor the evolution of 
this system. UBA has two polymorphs of almost equivalent free-energy and so is typically obtained as a polymorphic mixture. In situ 
PXRD uncovered a progression of polymorphs from UBA III to the thermodynamic polymorph UBA I, where different positions 
along the length of the tubular flow crystallizer 
correspond to different reaction times. Addition of 
UBA I seed crystals modified this pathway such 
that only UBA I was observed throughout, while 
transformation from UBA III into UBA I still oc-
curred in the presence of UBA III seeds. Infor-
mation regarding the mixing-dependent kinetics of 
the CBZ form II to III transformation was also un-
covered in a series of seeded and unseeded flow 
crystallization runs, despite atypical habit expres-
sion. These results illustrate the importance of cou-
pling controlled reaction environments with in situ 
XRD to study the phase relationships in polymor-
phic materials.  
INTRODUCTION 
The relative stabilities of polymorphic solid forms, the ability 
to selectively access individual polymorphs and the transitions 
between polymorphs, are all critical elements in the develop-
ment and processing of solid-state pharmaceutical materials.1, 2  
However, it can be difficult to predict crystallization routes and 
reproducibly select for a particular form, where post-crystalli-
zation analysis can only reveal limited information on the crys-
tallization process itself and can be unreliable due to issues with 
quenching, drying, and sample preparation.3  In order to control 
the formation of such materials, an understanding of their real-
time evolution in industrially-relevant environments is vital. X-
ray diffraction (XRD) is a key analytical method for examining 
such systems, but examples of in situ diffraction studies are cur-
rently limited to small-scale batch and microfluidic reactors.  
In order to better understand crystallization processes, more 
reproducible methods are required to control these processes 
over multiple length scales. Due to the inhomogeneity and irre-
producibility of batch crystallizers, flow technologies have re-
cently emerged as a highly effective means of achieving this 
goal.4 Continuous flow platforms that can simultaneously pro-
vide direct scale-out routes,5 narrow time resolution,6 repre-
sentative sampling,7 and high-throughput materials synthesis up 
to production-scale rates are particularly attractive.8 Im-
portantly, they can also be coupled to in situ analytical tech-
niques. However, these technologies are still in their infancy, 
and few examples exist where flow platforms – especially large-
scale platforms – have been used in conjunction with in situ 
analysis to evaluate crystallization pathways.9-13 Typically these 
have been limited to the production of sub-micron or nanopar-
ticle-sized inorganic materials11 or proteins,14 which present 
fewer challenges for blockage mitigation and back mixing. 
 
Additional in situ studies of crystallization processes have been 
conducted with smaller-scale microfluidic platforms using tech-
niques such as optical microscopy15 and small angle X-ray scat-
tering.16, 17 However, many time-resolved microfluidic studies 
have primarily focused on characterizing photoluminescent 
nanocrystals that can be monitored by fluorescence/absorption 
spectroscopy.18-20 The few examples of millifluidic studies us-
ing in situ XRD either focus on crystallization events occurring 
on the reactor walls21 or divert the crystallizing solution into an 
add-on slurry cell which is not an integral part of the crystal-
lizer.11, 22, For the latter case, this additional flow path can affect 
the crystallization environment and be prone to encrustation, 
and thus does not provide a representative expression of the 
crystallization pathway. Taddei and co-workers have demon-
strated a millifluidic microwave-assisted flow crystallization 
apparatus which incorporates in situ powder XRD (PXRD) 
without a separate slurry cell.10 However, due to the constraints 
of this reactor design, analysis is limited to a single location at 
the reactor outlet, preventing the investigation of reaction dy-
namics. These issues are addressed here, where we have suc-
cessfully integrated a continuous millifluidic crystallizer with 
in situ synchrotron PXRD at multiple analysis points. 
We introduce the Kinetically Regulated Automated Input 
Crystallizer for Diffraction (KRAIC-D; Fig. 1), and demon-
strate its use to study the crystallization pathways of two im-
portant polymorphic pharmaceutical model compounds: car-
bamazepine (CBZ) and urea:barbituric acid (UBA). The design 
of the KRAIC-D crystallizer is based upon the previously pub-
lished KRAIC,13, 23-25 with a spatial rearrangement and inclusion 
of features such as X-ray transparent windows necessary for the 
implementation of in situ PXRD. X-ray diffraction provides 
critical structural information and, importantly, can be applied 
to all crystalline materials. Additionally, our tri-segmented flow 
regime is shown to offer highly reproducible crystallization en-
vironments by limiting the influence of unwanted surfaces on 
crystallization, while the scale of the KRAIC-D allows for the 
analysis of large organic crystals (>100 m) inaccessible with 
microfluidics.  
An inherent property of segmented flow technologies is that, 
in steady flow, the residence or dwell time of particular fluid 
segments can be easily determined from their position along the 
flow path.26 As such, analysis of a particular position within the 
flow will continually yield information from a single reaction 
time-point, irrespective of fluid motion or the transience of the 
Figure 1: (a) Diagram of the analysis module of the KRAIC-D operating in transmission mode with X-ray penetration initiated behind the 
window section. (b) Enlarged view of a single analysis window comprising a Kapton tube and two polytetrafluoroethylene (PTFE) unions 
(inset shows the triphasic solution, air, and carrier fluid slug flow). (c) Accumulation of 2D diffraction pattern frames from 100 ms exposures 
that are combined to achieve a (d) 1D diffraction plot (shown here is a combined scan of carbamazepine form II). 
 
process being studied. Thus, collecting diffraction data from a 
range of positions within a device enables step-by-step elucida-
tion of dynamic crystallization pathways with excellent repro-
ducibility. This concept has been successfully reported in a mi-
crofluidic system27 and is adapted here at the milliliter-scale to 
uncover the crystallization pathways of CBZ and UBA in re-
sponse to different seeding regimes. In addition to uncovering 
information regarding the mixing-dependent kinetics of the 
CBZ form II to III transformation, our results also provide clar-
ity regarding the stability of UBA polymorphs under solvated 
or non-solvated conditions. 
EXPERIMENTAL SECTION 
Materials: Urea and barbituric acid were purchased from 
Sigma Aldrich (Steinheim, Germany) and carbamazepine was 
purchased from Molekula (Darlington, UK). All reagents were 
used without further purification. Laboratory grade solvents 
(methanol and ethanol) purchased from Sigma Aldrich were 
used for all crystallizations. 
KRAIC-D Design and Operation: The KRAIC-D crystal-
lizer consists of two modules: a control module containing fluid 
pumps and temperature control apparatus (Fig. S1) and an anal-
ysis module comprising the bulk of the flow reactor length and 
low scattering X-ray analysis windows (Fig. 1a). The analysis 
module was built from an optomechanical breadboard 
(Thorlabs) comprising two columns for coiling the reactor tub-
ing and can be mounted onto the motorized stage of the beam-
line experimental hutch for beam positioning and data acquisi-
tion. Each analysis window is made from a seamless polyimide 
tube (Kapton, American Durafilm) that is integrated into the 
main fluorinated ethylene propylene (FEP, Omega) reactor tub-
ing using custom-machined polytetrafluoroethylene (PTFE) un-
ions (Fig. 1b and Fig. S4). Crystallizations were conducted in a 
tri-segmented flow of solvent, carrier fluid, and air to isolate 
reactions from the reactor walls and improve mixing and time-
resolution (through minimization of Taylor dispersion28). The 
air phase aids in consistent flow segmentation and prevents co-
alescence of solution slugs in inclined sections of tubing. Cool-
ing crystallizations of UBA and CBZ (from methanol and etha-
nol respectively) were studied unseeded and with the addition 
of slurries of seed crystals at two different seeding ports (see 
Supporting Information). Heated feed solutions were air-cooled 
to ambient temperature along the length of the crystallizer once 
segmentation was established, and seed slurries were prepared 
and added at room temperature.  
In situ Powder XRD: Data were collected at the High-Reso-
lution Powder Diffraction beamline (I11) of Diamond Light 
Source. Complete PXRD datasets were obtained through a se-
rial crystallography-like approach, combining reflections from 
individual diffraction events caused by the flow of crystals past 
an X-ray beam.29 In contrast to injector-based serial crystallog-
raphy,30, 31 crystals are grown in situ, and different positions 
along the flow channel correspond to different times in the crys-
tallization process.27 Five separate multi-frame scans, each of 
10.1 s total exposure time, from a single position along the flow 
are combined to produce a serial diffraction pattern for each 
time point (Fig. 1c). Each pattern is then azimuthally integrated 
and presented at the Cu K characteristic wavelength (1.5406 
Å) for comparison to reference data (Fig. 1d). Full experimental 
details, including detailed KRAIC-D designs and data capture 
and analysis procedures, are available in the Supporting Infor-
mation. 
RESULTS AND DISCUSSION 
This study focused on the crystallization of two model phar-
maceutical compounds – UBA and CBZ – to determine the rel-
ative stabilities of their different polymorphic forms, and the 
pathways by which they form. The co-crystalline system of 
UBA is a promising high solubility form of the barbiturate pre-
cursor, barbituric acid. Three atmospheric pressure polymorphs 
of UBA are known, where a mixture of UBA I and III is often 
obtained from cooling crystallization. Although some studies 
report contradicting results,32, 33 we have previously found UBA 
I to be the stable polymorph under normal cooling crystalliza-
tion conditions.34  However, the free energy levels of forms I 
and III are thought to be very close due to their concomitant 
production. UBA is therefore an ideal model for in situ XRD 
analysis. 
CBZ is a high-profile pharmaceutical model molecule35 and 
is the active pharmaceutical ingredient in Tegretol®, which is 
used as an anti-seizure medication and to relieve neuropathic 
pain. CBZ can crystallize in one of five polymorphs, of which 
CBZ III is the most stable under atmospheric pressure and CBZ 
II is often the first to form during crystallization from solution.36 
A transformation between these two polymorphs can be ex-
pected during crystallization, whilst the initial polymorphic ex-
pression can be dependent on the mixing conditions. 
UBA crystallization:  UBA was crystallized in methanol un-
der cooling in the absence and presence of UBA seed crystals 
in the KRAIC-D crystallizer. Initial offline PXRD analysis of 
unseeded material revealed a mixture of UBA I and III (Fig. 
S13), as has also been reported in previous studies.34 This con-
comitant formation has led to some debate regarding the iden-
tity of the thermodynamic polymorph.32 During unseeded 
KRAIC-D experiments pure UBA III was observed at Window 
1 (4.6 min, 6.4 m), but at Window 2 (6.9 min, 9.0 m) peaks of 
UBA I can clearly be seen, notably at 28.9 2 (3.08 Å) corre-
sponding to the (114̅) reflection (Fig. 2).  Furthermore, the in-
tensity of this UBA I peak with respect to UBA III peaks in-
creases in the data obtained from Window 3 (9.0 min, 11.7 m). 
This suggests that UBA III is transforming into UBA I in solu-
tion with time and lends additional support to the identification 
of UBA III as the kinetic polymorph and UBA I as the thermo-
dynamic polymorph. 
 
Figure 2: Unseeded cooling crystallization of UBA in the KRAIC-
D showing a progression of form III to form I in PXRD patterns 
obtained from Window 1 to 3. The dotted lines are a guide to the 
eye for identification of characteristic peaks of each polymorph 
(UBA I and III). The scale of the experimental diffraction patterns 
 
has been adjusted for clarity and converted into Cu K wavelength 
for comparison to reference data. 
Experiments seeded with UBA I and UBA III crystals rein-
force this interpretation. In experiments where seeds of UBA I 
were added at the onset of the reaction (immediately after seg-
mentation is established, hereafter termed ‘pre-nucleation’, Fig. 
S5), only UBA I was observed along the entire crystallizer 
length (Fig. 3a and Fig. S14). Conversely, experiments with 
pre-nucleation seeding of UBA III again showed a slight con-
version to UBA I by Window 2 (notably from peaks at 17.6 and 
28.9), confirming that UBA I is the thermodynamic form (Fig. 
3a and Fig. S15).  Furthermore, experiments seeded with UBA 
III at 9.1 m, after Window 2, (i.e. after where UBA I formed in 
the unseeded experiments, hereafter termed ‘post-nucleation’) 
still showed evidence of conversion of UBA III to I between 
Windows 2 and 3, notably through peaks at 17.6 and 28.9° (Fig. 
3b). 
 
Figure 3: (a) PXRD comparing UBA pre-nucleation seeded crys-
tallization runs from Window 2. (b) PXRD plots of UBA form III 
post-nucleation seeded run showing partial transformation to form 
I across Windows 2 and 3. The dotted lines are a guide to the eye 
for identification of characteristic peaks of each polymorph (UBA 
I and III). The scale of the experimental diffraction patterns has 
been adjusted for clarity and converted into Cu K wavelength for 
comparison to reference data. 
Mapping crystal growth via relative diffraction intensity ob-
served at each window (as defined by the area under the diffrac-
tion pattern or integrated intensity, see Supporting Information) 
shows that there is very little crystal growth between Windows 
1 and 2 in the unseeded experiments (Fig. 4a). At Window 3 
there is a large increase in diffraction intensity suggesting this 
system is nucleation limited with fast growth. In accordance 
with this, both experiments seeded pre-nucleation show signif-
icant growth between each window. Comparing the pre-nucle-
ation seeded experiments, seeding with UBA I (Fig. 4b) pro-
duces a much greater increase in apparent crystal growth be-
tween window 1 and 2 than that observed for experiments 
seeded with UBA III (Fig. 4c). This could be attributed to the 
polymorphic conversion of UBA form III to I during the ana-
lyzed time period in UBA III seeded runs, not present when 
seeding with UBA form I. 
 
Figure 4: Box plots of diffraction intensity for (a) unseeded, (b) 
pre-nucleation form I seeded, and (c) pre-nucleation form III 
seeded UBA KRAIC-D experiments. N.B. red lines indicate the 
median intensity found in all frames containing non-solvent dif-
fraction, boxes encompass the inner quartile range (IQR, be-
tween upper and lower quartiles), and data within 1.5xIQR are 
 
represented as whiskers. Asterisks indicate significant differ-
ence (p < 0.05). 
In contrast to our in situ results, offline analysis of dry UBA 
I and III seeds after 12 months of storage at 18 °C in a standard 
laboratory environment showed some transformation of UBA I 
to UBA III, whilst UBA III seeds remained stable (Fig. S16). 
However, an additional offline experiment in which a slurry of 
these UBA III seeds was prepared in methanol for 4 mins again 
showed significant but incomplete transformation to UBA I 
(Fig S16, top). Previous literature reports have described the 
solid state transformation of UBA I to III32, 33, 37 and solution 
state transformation of UBA III to I.34 In light of the findings 
reported here and the previous literature, we propose that the 
relative stability of the polymorph of UBA is dependent on en-
vironment, with UBA III being the most stable in air and UBA 
I being the most stable in solution. 
CBZ crystallization:  The crystallization of CBZ from etha-
nol with and without the addition of CBZ III seeds was studied 
in the KRAIC-D. In unseeded experiments, the metastable 
form, CBZ II, was observed throughout the crystallization pro-
cess (observation points at 8 min 30 s, 12 min 20 s and 16 min 
20 s, Fig. S17). Conversely, seeding the flow pre-nucleation 
with the thermodynamic form (CBZ III) resulted in the growth 
of exclusively CBZ III along the crystallizer length (Fig. S18). 
Further, when these same CBZ III seeds were added post-nu-
cleation of CBZ II (at 12.7 min crystallization time, immedi-
ately after Window 2), all material appeared to have been con-
verted to CBZ III by Window 3 (Fig. 5).  
 
Figure 5: PXRD patterns obtained from CBZ cooling crystalliza-
tion within the KRAIC-D with seeding of CBZ III post-nucleation 
(after Window 2). The dotted lines are a guide to the eye for iden-
tification of characteristic peaks of each polymorph (CBZ II and 
III). The scale of the experimental diffraction patterns has been ad-
justed for clarity and converted into Cu K wavelength for com-
parison to reference data. 
CBZ is well known to typically present morphologically as 
needles for CBZ II and as blocks for CBZ III. However, despite 
only detecting CBZ III by PXRD after post-nucleation seeding, 
aggregated needles were the main habit observed, in addition to 
a low proportion of small blocks and more plate-like crystals 
(video available in the Supporting Information). Additionally, 
offline slurrying experiments of CBZ II and III seed mixtures  
indicated there should be only a minor polymorphic transition 
(II → III) within the timeframe between seeding at 12.7 min and 
detection at Window 3 (16.7 min; Fig. S19).  
To test whether the diffraction of the more abundant needle 
crystals was obscured by the more naturally intensely diffract-
ing prisms through combining diffraction patterns (comprising 
255 individual frames), we analyzed individual 100 ms diffrac-
tion frames from both before and after the addition of CBZ III 
seeds (Fig.6). At Window 2, prior to the addition of CBZ III 
seeds), diffraction peaks captured at 13.2°, 18.5°, and 24.4° cor-
responding to the (140)/ (410), (211), and (431) reflections of 
CBZ II enabled its detection from a single frame (Fig. 6a). Sub-
sequently, the combination of successive frames and scans con-
firmed the identification of CBZ II, with increased diffraction 
statistics of these peaks and the detection of additional reflec-
tions. However, at Window 3, even analysis of individual 
frames did not reveal any reflections that could have been pro-
duced by CBZ II crystals (Fig. 6b). Multiple diffraction peaks 
unique to CBZ III were observed in individual frames, notably 
at 15.3° and 19.5° corresponding to the (110) and (113̅) reflec-
tions. Subsequent combination of frames/scans yielded new re-
flections consistent with the presence of CBZ III, improving the 
agreement of relative peak heights with reference data. There-
fore, due to only CBZ III being observed via PXRD and the 
high percentage of needles observed visually, we conclude that 
this must be a rare case of CBZ III presenting as needle crystals 
as was previously reported from cooling crystallization in iso-
propanol38 or in the presence of surfactants.39 Additionally, we 
rationalize the faster conversion of CBZ II to CBZ III observed 
in the KRAIC-D compared to batch slurrying techniques by the 
intensified mixing induced within the segmented flow environ-
ment.40 
 
Figure 6: PXRD patterns of CBZ obtained from post-nucleation 
seeded cooling crystallization in the KRAIC-D at (a) Window 2 
 
and (b) Window 3, comparing the data obtained from the combined 
scan method (5 scans), a single scan with a total of 51 exposures 
and a singular 100 ms exposure (frame). The dotted lines are a 
guide to the eye for the identification of selected characteristic 
peaks of CBZ II and III in (a) and (b), respectively. The scale of the 
experimental diffraction patterns has been adjusted for clarity and 
converted into Cu K wavelength for comparison to reference data. 
The growth profile of unseeded CBZ crystallization shows a 
significant exponential increase in relative diffraction intensity 
across the three analysis windows (Fig. 7a). Pre-nucleation 
seeded crystallization with CBZ III, however, achieves steady-
state intensity prior to Window 1 (Fig. 7b), implying thermody-
namic equilibrium has occurred before our first point of analy-
sis (8 min 30 s). This is in contrast to the latent growth observed 
for unseeded UBA and linear growth profiles for pre-nucleation 
seeded crystallization with either UBA I or III. 
 
Figure 7: Box plots of diffraction intensity for (a) unseeded and (b) 
pre-nucleation form III seeded CBZ KRAIC-D experiments. N.B. 
red lines indicate the median intensity found in all frames contain-
ing non-solvent diffraction, boxes encompass the inner quartile 
range (IQR, between upper and lower quartiles), and data within 
1.5xIQR are represented as whiskers. Asterisks indicate significant 
difference (p < 0.05). 
CONCLUSIONS  
Polymorphic transitions and stability during cooling crystal-
lization in an industrially relevant crystallizer were uncovered 
through in situ powder X-ray diffraction (PXRD) analysis. The 
relationship between crystallizer length and reaction time in the 
milli-scale tubular crystallizer (KRAIC-D) provided reliable 
and reproducible access to transient crystallization events at the 
required time resolution. With this platform, we studied the 
crystallization pathways of two important pharmaceutical sys-
tems, urea:barbituric acid (UBA) and carbamazepine (CBZ), 
and assessed their polymorphism during unassisted crystalliza-
tion and in response to various seeding regimes. For UBA, these 
experiments helped determine the relative stability of poly-
morphs in solution vs the solid state. During solution-based 
crystallization and slurrying, UBA III rapidly transforms into 
UBA I in the presence and absence of seed crystals. In contrast, 
dry crystals of UBA I transform into UBA III under normal la-
boratory conditions within 12 months, highlighting the need for 
accurate knowledge of the media-dependent stability (in this 
case methanol vs air) of a solid form as essential for designing 
routes to accessing effective pharmaceuticals.  
Experiments with CBZ confirmed the established form II to 
form III nucleation and growth pathway and illustrated the sen-
sitivity of this pathway to seeding and mixing intensity. Nucle-
ation of CBZ form II could be bypassed completely or existent 
form II crystals begin rapid transformation depending on the lo-
cation of form III seeding. From a technical standpoint, deeper 
evaluation of CBZ data also showed that a single 100 ms dif-
fraction frame from the KRAIC-D can yield sufficient data to 
identify polymorph. 
The KRAIC-D complements previously reported examples 
of inline PXRD analysis10, 11, 21, 22 through direct inclusion of 
multiple non-invasive analysis windows with low background 
scattering. This new method also builds on our earlier work in 
microfluidic PXRD.27 While microfluidic devices have a much 
smaller footprint in the beamline experimental hutch and can be 
more easily incorporated with additional analysis windows/ res-
idence time points, they also are more prone to fouling and 
blockage from large crystals or in rapid precipitation scenarios 
than their milli-scale counterparts. Furthermore, the larger 
channel cross-section and slower relative speed of millifluidic 
flows are not as demanding of beamline hardware (i.e. do not 
require microfocused X-ray beams or <100 ms exposures), and 
thus lower the barrier to performing in situ structural analysis 
of target materials. We envisage this technique will enable new 
research into understanding and ultimately controlling crystal-
lization processes. In particular, the ability to apply this strategy 
to large-scale crystallizers will facilitate expedited production 
and quality assurance of pharmaceuticals and agrochemicals in 
manufacturing environments. 
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